Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$100000.0.

  • Ptc Therapeutics' Gains from Investment Securities fell 10150.06% to -$100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year increase of 33504.61%. This contributed to the annual value of $17.6 million for FY2024, which is 11374.31% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Gains from Investment Securities stood at -$100000.0, which was down 10150.06% from $36.1 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Gains from Investment Securities peaked at $80.3 million during Q2 2022, and registered a low of -$128.9 million during Q2 2023.
  • For the 5-year period, Ptc Therapeutics' Gains from Investment Securities averaged around -$1.4 million, with its median value being $2.0 million (2024).
  • Per our database at Business Quant, Ptc Therapeutics' Gains from Investment Securities crashed by 262727.27% in 2021 and then surged by 223552.33% in 2022.
  • Ptc Therapeutics' Gains from Investment Securities (Quarter) stood at -$3.9 million in 2021, then surged by 113.44% to $523000.0 in 2022, then tumbled by 616.25% to -$2.7 million in 2023, then soared by 276.63% to $4.8 million in 2024, then tumbled by 102.1% to -$100000.0 in 2025.
  • Its Gains from Investment Securities was -$100000.0 in Q3 2025, compared to $36.1 million in Q2 2025 and $3.0 million in Q1 2025.